L 838417

Drug Profile

L 838417

Latest Information Update: 25 Jun 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Anxiolytics; Fluorobenzenes; Pyridazines; Small molecules; Triazoles
  • Mechanism of Action GABA receptor agonists; GABA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders

Most Recent Events

  • 14 Feb 2001 A study has been added to the Anxiety Disorders pharmacodynamics section
  • 08 Feb 2001 New profile
  • 08 Feb 2001 Preclinical development for Anxiety disorders in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top